Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
SS-31 (generic name elamipretide, development names MTP-131 and Bendavia, brand name Forzinity™) is a synthetic mitochondria-targeted tetrapeptide with the sequence D-Arg-2′,6′-dimethylTyrosine-Lys-Phe-NH₂. The compound belongs to the Szeto-Schiller (SS) peptide family developed by Dr. Hazel Szeto and Dr. Peter Schiller at Weill Cornell Medical College in the early 2000s. SS-31 received FDA Accelerated Approval on September 19, 2025, as Forzinity for Barth syndrome, making it the first and only FDA-approved mitochondria-targeted peptide.
SS-31's defining characteristic is extreme mitochondrial selectivity. The compound concentrates in the inner mitochondrial membrane (IMM) at >1000-fold higher concentrations than cytoplasm through electrostatic interaction between its positively charged residues and cardiolipin, the signature phospholipid found almost exclusively in the IMM. This selective targeting doesn't require conventional targeting signal sequences, provides direct access to the site of oxidative phosphorylation, distinguishes SS-31 from other antioxidants and mitochondrial agents, and enables tissue-independent mitochondrial action.
SS-31 is fundamentally different from the mitochondrial-derived peptides (MDPs) MOTS-c ([[mots-c]]) and Humanin ([[humanin]]):
- SS-31 (Elamipretide): Synthetic and exogenous; designed as a mitochondrial drug; tetrapeptide with non-natural amino acids; cardiolipin binding mechanism
- MOTS-c: Endogenous 16 aa peptide; encoded by mitochondrial DNA (12S rRNA region); AMPK activation + nuclear translocation
- Humanin: Endogenous 24 aa peptide; encoded by mitochondrial DNA (16S rRNA region); Bax inhibition + GP130 signaling
This distinction is fundamental: SS-31 is a designed mitochondrial drug, while MDPs are endogenous mitochondrial peptides. The mechanism difference matters scientifically and practically. Users should not confuse SS-31 with MOTS-c or Humanin despite all three being 'mitochondrial peptides.'
SS-31 has the strongest evidence profile of any mitochondrial peptide: Phase 1-3 trials across multiple indications, pharmaceutical-grade mechanistic characterization (cardiolipin binding biochemically documented in British Journal of Pharmacology 2014), and now full FDA approval (Forzinity, September 2025) for Barth syndrome. The approval is narrow but real: specifically for Barth syndrome (X-linked TAZ gene disorder, ~150-200 US patients) in adults and pediatric patients ≥30 kg, at 40 mg SC daily, with confirmatory trials required per accelerated approval pathway. Off-label use for general longevity, anti-aging, or athletic performance is widespread but lacks Phase 3 validation for those populations.
The Barth syndrome approval is mechanistically rational: Barth syndrome is caused by TAZ gene mutations encoding tafazzin, an enzyme that remodels cardiolipin; patients have defective cardiolipin composition. A cardiolipin-stabilizing drug directly addresses the molecular defect. This is why Barth syndrome was the breakthrough indication despite mixed results in cardiovascular trials (EMBRACE STEMI did not meet primary endpoint; TOPCAT-HFpEF and PROGRESS-HF showed mixed results in heart failure). The cardiovascular failures contrast with Barth syndrome success: for users contemplating SS-31 in non-medical contexts, this evidence asymmetry matters.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Forzinity™ (elamipretide HCl) SC, FDA-approved | ~2-4 hours plasma; longer mitochondrial retention |
| Intravenous SS-31 (clinical trials) | Short plasma; longer mitochondrial retention |
| Subcutaneous SS-31 (research / non-medical) | ~2-4 hours plasma |
| Eye drops (AMD trials) | Local ocular |
| Oral SS-31 | Not feasible |
What it does
Main effects
- FDA-approved for Barth syndrome (September 19, 2025) as Forzinity™: Accelerated Approval based on TAZPOWER Phase 2/3; 40 mg SC daily; adults and pediatric ≥30 kg; first FDA-approved mitochondria-targeted peptide; confirmatory trials required
- Cardiolipin binding in the inner mitochondrial membrane: primary mechanism; SS-31 concentrates in IMM at >1000-fold higher than cytoplasm via electrostatic interaction with cardiolipin (signature IMM phospholipid)
- Cristae structure stabilization: cardiolipin is essential for cristae (folded inner membrane); SS-31 preserves cristae morphology under disease and aging conditions
- Electron transport chain supercomplex stabilization: optimizes ETC efficiency; reduces electron leak from Complexes I and III; increases ATP yield per oxygen consumed
- Reduced reactive oxygen species (ROS) production at the source: distinct from antioxidants that scavenge ROS; SS-31 reduces ROS production by improving ETC efficiency rather than scavenging
- Mitochondrial bioenergetics restoration across diverse tissues: cardiac, skeletal muscle, kidney, retinal, brain; tissue-independent mitochondrial mechanism
- Distinct from MDPs (MOTS-c, Humanin): SS-31 is synthetic and exogenous; MDPs are endogenous and mitochondrial-DNA-encoded; SS-31 binds cardiolipin while MDPs engage AMPK (MOTS-c) or Bax (Humanin)
- Investigational uses: Heart failure (EMBRACE STEMI Phase 2: did NOT meet primary endpoint; TOPCAT-HFpEF and PROGRESS-HF mixed); primary mitochondrial myopathy (MMPOWER Phase 1/2; NuPOWER Phase 3); AMD (ReCLAIM-2 Phase 2b; ReNEW Phase 3 planned); Friedreich's ataxia (CHOP investigator-initiated)
- Stealth BioTherapeutics commercial trajectory: founded 2006 by Hazel Szeto; multiple Phase 2 failures in cardiovascular; 2022 acquisition by Morningside Venture (privately held); 2025 FDA approval for Barth syndrome
What to watch for
Common side effects
- Generally favorable safety profile across multiple Phase 1-3 trials; no major systemic toxicity; no black box warnings in approved Forzinity labeling
- Injection site reactions (most common): pain, redness, swelling at injection site; generally mild and self-limited; site rotation helpful
- Headache (common): generally mild and self-limited; less common with continued treatment
- Less common adverse events: nausea, fatigue, dizziness, mild GI symptoms
- Approved indication is narrow: Forzinity approval is specifically for Barth syndrome (rare X-linked TAZ gene disorder, ~150-200 US patients); off-label use for general longevity, anti-aging, or athletic performance lacks Phase 3 evidence in those populations
- Off-label / non-medical use disconnect: common non-medical applications (general longevity, athletic performance, combined with MOTS-c) do not match the approved indication; mechanism could theoretically extend but Phase 3 validation does not
- Mixed cardiovascular trial results: EMBRACE STEMI did NOT meet primary endpoint; TOPCAT-HFpEF and PROGRESS-HF showed mixed results; mechanism interest persists despite trial setbacks
- Pediatric approval limited to ≥30 kg: insufficient data for approval in smaller pediatric Barth syndrome patients
- Confirmatory trials required per Accelerated Approval pathway: full approval contingent on additional evidence
- Cost reality: Forzinity is specialty-pharmacy-distributed and expensive; insurance coverage for approved indication; research-chemical-grade SS-31 used off label is not made to pharmaceutical manufacturing standards, so its purity and concentration are unverified
- Research chemical quality concerns: identity verification important (Dmt is unusual amino acid requiring specialized synthesis); concentration variability; sterility for injection; disulfide-bond-free structure simpler than some peptides
- Theoretical effects on cancer cell mitochondria: cardiolipin-stabilization in cancer cells theoretically possible; long-term effects of supraphysiological mitochondrial targeting unclear
- Pregnancy/lactation safety: limited data
- Not WADA-prohibited as of 2025-2026 list (verify current status before use in tested sport)
Key facts
Key facts worth knowing
- SS-31 is a synthetic tetrapeptide (4 amino acids) with sequence D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH₂ (also written D-Arg-Dmt-Lys-Phe-NH₂). The 2′,6′-dimethyltyrosine (Dmt) is an unusual non-natural amino acid critical for mitochondrial targeting properties. Molecular weight 639.79 Da. CAS 736992-21-5. Smallest mitochondrial peptide in the library.
- FDA Accelerated Approval September 19, 2025 as Forzinity™ (elamipretide HCl) for Barth syndrome in adults and pediatric patients weighing ≥30 kg. First FDA approval for any mitochondria-targeted peptide. Sponsor: Stealth BioTherapeutics. Orphan Drug Designation and Fast Track Designation. Confirmatory trials required per accelerated approval pathway. FDA Approval Documentation. Forzinity™ (elamipretide HCl) for Barth syndrome. September 19, 2025. Stealth BioTherapeutics.
- Discovered serendipitously by Hazel Szeto and Peter Schiller at Weill Cornell Medical College in the early 2000s. They were studying opioid peptide analogs and discovered unexpected mitochondrial accumulation properties. The series was named after the discoverers (Szeto-Schiller peptides). SS-02 and SS-31 emerged as the most studied family members. Szeto founded Stealth BioTherapeutics in 2006 to commercialize the platform. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clinical Pharmacology and Therapeutics 2014;96(6):672-683.
- Mechanism: cardiolipin binding in inner mitochondrial membrane (IMM). Cardiolipin is a unique phospholipid found almost exclusively in the IMM, with four fatty acid tails (vs typical two) and a conical molecular shape facilitating membrane curvature. SS-31's positively charged D-Arg and Lys residues electrostatically interact with cardiolipin's negative charge; aromatic Dmt and Phe residues insert into the membrane. SS-31 concentrates in IMM at >1000-fold higher than cytoplasm through this interaction. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 2014;171(8):2029-2050.Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology 2013;24(8):1250-1261.
- SS-31 is fundamentally different from MDPs (MOTS-c, Humanin). SS-31 is synthetic and exogenous, a designed mitochondrial drug. MOTS-c and Humanin are endogenous and mitochondrial-DNA-encoded, bioactive peptides naturally produced by mitochondria. The mechanism difference matters: SS-31 binds cardiolipin; MOTS-c activates AMPK and translocates to nucleus; Humanin inhibits Bax and signals through GP130. Users should not confuse SS-31 with MDPs despite all three being 'mitochondrial peptides.'
- Barth syndrome is the mechanistically rational approval indication. Barth syndrome is X-linked, caused by mutations in the TAZ gene encoding tafazzin, an enzyme involved in cardiolipin remodeling. Patients have defective cardiolipin composition → cardiomyopathy, skeletal myopathy, neutropenia, growth delays, significantly shortened lifespan. A cardiolipin-stabilizing drug directly addresses this molecular defect, exactly why this disease became the breakthrough indication.
- TAZPOWER Phase 2/3 trial: basis for FDA approval. 28-week randomized, double-blind, placebo-controlled trial at Johns Hopkins Hospital. 12 patients with genetically confirmed Barth syndrome. Subcutaneous elamipretide 40 mg/day in two 12-week treatment periods. Primary endpoint: 6-minute walk test. Trends toward improvement in primary; statistically significant improvements in secondary endpoints (five-times sit-to-stand test). Open-label extension showed sustained benefits (Genetics in Medicine 2023). 8 of 10 initial participants reached 168-week visit. Hilary Vernon (Johns Hopkins) led the trial design working with Stealth. Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genetics in Medicine 2021;23:471-478.Hornby B, et al. TAZPOWER long-term extension data. Genetics in Medicine 2023.
- Cell-penetrating without classical mechanisms. SS-31 enters cells and concentrates in mitochondria without requiring classical receptors or active transport, driven by electrostatic interaction with cardiolipin. This is mechanistically distinct from MitoQ (uses triphenylphosphonium (TPP+) for targeting) and other mitochondrial targeting approaches.
- Mixed Phase 2/3 results in other indications. Cardiovascular trials had setbacks: EMBRACE STEMI (STEMI reperfusion injury) did NOT meet primary endpoint; TOPCAT-HFpEF and PROGRESS-HF (heart failure) showed mixed results. MMPOWER program for primary mitochondrial myopathy advanced to NuPOWER Phase 3 (ongoing). ReCLAIM-2 Phase 2b for AMD showed efficacy signals; ReNEW Phase 3 planned. Friedreich's ataxia in CHOP investigator-initiated Phase 1/2. The Barth syndrome success contrasts with mixed cardiovascular results, relevant context for off-label use.
- Stealth BioTherapeutics commercial trajectory. Founded 2006 by Hazel Szeto. Multiple clinical trials conducted across cardiovascular, mitochondrial myopathy, AMD, and Barth syndrome indications. Acquired November 2022 by Morningside Venture consortium (privately held). 2025 FDA approval for Barth syndrome culminated 25 years of development. Continues elamipretide development for additional indications under private ownership.
Legal status
Legal status
FDA-APPROVED as Forzinity™ (September 19, 2025) for Barth syndrome in adults and pediatric patients weighing ≥30 kg via Accelerated Approval pathway. Orphan Drug Designation and Fast Track Designation. First FDA-approved mitochondria-targeted peptide. Confirmatory trials required. All other indications investigational or off-label. Available through specialty pharmacy for approved indication. Research chemical SS-31 widely available in legal gray area. Not WADA-prohibited (verify current status).